CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Recurrent Acute Myeloid Leukemia Interventions:   Drug: Gemtuzumab Ozogamicin;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials